diaDexus, Inc. announced the appointment of Mika Newton as General Manager of the clinical development services business unit to partner with pharmaceutical companies interested in using the company's proprietary cardiac biomarkers in their clinical development programs. He joined diaDexus in January 2015 as general manager of the clinical development service business to partner with pharmaceutical companies by providing sampling and testing services to support their clinical development of cardiovascular therapies or post-approval cardiovascular safety studies. Prior to joining diaDexus, Mr. Newton was the senior vice president of client and market development for Evidera.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
2021 | Diadexus, Inc. Went Out of Business | CI |
2018 | Motion for Asset Sale Approved for Diadexus, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 410 | |
-26.96% | 1.42B | |
-19.77% | 56.73M |
- Stock Market
- Equities
- DDXSQ Stock
- News Diadexus, Inc.
- DiaDexus, Inc. Appoints Mika Newton to Lead Clinical Development Service Business